

PLACEBO (FORMULE 515 AP-HP): A FRENCH OBSERVATIONAL SURVEY

DI 011

Léa LAMIRAND, Jean-Meidi ALILI, Marie-Pierre BERLEUR, Marie-Caroline HUSSON

Regulatory, Pharmaceutical and Medical Department, Pharmaceutical Establishment of Paris Hospitals Group, AP-HP, Paris, France
jean-meidi.alili@aphp.fr ; marie-caroline.husson@aphp.fr

Background and Objective

Pharmaceutical Establishment of Paris Hospitals Group (PE AP-HP) provides French health care professionals with placebo hospital preparation 'Formule 515 AP-HP tablet' (F515).

Observational survey conducted in French Hospitals

→ To evaluate the therapeutic interest of F515

Setting and Method

Survey: July to December 2018
in **79 French hospitals**
users of F515 during the past 4 years

Pharmacists

Clinicians

Main outcome measures

Clinical interest?

Standardized questionnaire

Uses?

Mean duration of the treatment?

Results - Discussion

➤ Seventy-nine hospitals were contacted, 39/79 (49%) answered the questionnaire.

➤ The survey showed:

Medico-judicial units and administrative detention centers for anxious, alcoholic, or drug-addicted patients

Otorhinolaryngology for tinnitus (cochlear implants)

Follow-up care and rehabilitation, internal and polyvalent medicine for the treatment of pain, anxiety and insomnia

PRESCRIPTIONS IN VARIOUS CLINICAL WARDS

Allergology

Psychiatry

Geriatric

NUMEROUS THERAPEUTIC USES

Hypnotic

Anxiolytic

Analgesic

Allergology
(drug re-introduction test)

Otorhinolaryngology
(cochlear implanted patients) for treating tinnitus

SHORT DURATION OF TREATMENT

Most often **few days to 1 month** and **adapted to each patient**
Few prolonged treatments (3-4 months) have been reported

UNIT PACKAGING

very appreciated by users

Eighteen hospitals (18/39) declared THEY WERE STILL INTERESTED IN USING F515 IN THE FUTURE

10/39 were not
11/39 didn't answer

Some non-respondents to this survey may have been embarrassed due to the **ethical issues** raised by the use of this particular drug.

Conclusion

- The **therapeutic interest** of F515 was **confirmed** by most professionals in this survey.
- It is appropriate that **PE AP-HP continue to manufacture** this drug for French hospitals.